Blood vessels made through tissue engineering are being trialled in humans and may provide a future source of grafts from coronary applications. That is the latest from a California-based company, Cytograft, who presented details of their methods and current human trial at the AHA meeting. Todd McAllister told Audio Medica how it all works.
[audio:https://www.audiomedica.com/podcasting/aha2005/Todd_McAllister.mp3]
Heart Attacks Drop After Smoking Ban in Ireland 5 Sep, 2007 Audio Journal of Cardiovascular Medicine 11.1, January 2005 8 Jan, 2006 
Polypill—even better for coronary prevention among those at high risk 12 Nov, 2012 Hypertension: Pressure Different at the Centre 16 Nov, 2005 
COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
